Hematopoietic Stem Cell Transplantation (HSCT) remains a cornerstone therapy for a wide spectrum of hematologic malignancies, congenital immunodeficiencies, and inherited metabolic disorders. Over the past decade, significant scientific and clinical advancements have reshaped HSCT, extending its curative potential while mitigating associated risks. Progress in donor selection, including high-resolution HLA typing and the widespread use of haploidentical donors, has expanded global transplant accessibility. Innovations in conditioning regimens such as reduced-intensity approaches and antibody-drug conjugates have optimized the balance between efficacy and toxicity, enabling safer procedures for older and medically fragile patients. Parallel developments in graft engineering, immune modulation, and cellular therapy integration have transformed post-transplant outcomes, particularly through the introduction of post-transplant cyclophosphamide, regulatory T-cell infusion, and NK-cell–based strategies to control Graft-Versus-Host Disease (GVHD). The emergence of gene-editing technologies, including CRISPR/Cas9-mediated autologous transplantation, has further broadened the therapeutic frontier for genetic and hematologic disorders. Advances in infection prophylaxis, supportive care, and long-term survivorship management continue to improve quality of life and survival rates. Despite these achievements, persistent challenges such as chronic GVHD, relapse, donor scarcity, and socioeconomic disparities underscore the need for continued innovation. This review synthesizes contemporary breakthroughs in HSCT biology, technology, and clinical application, critically examines unresolved barriers, and highlights future directions, including Artificial Intelligence (AI)-driven predictive analytics, universal donor platforms, and equitable global access strategies.
Research Article | Open Access | Download Full Text
Volume 2 | Issue 1 | Year 2026 | Article Id: RLS-V2I1P102 DOI: https://doi.org/10.59232/RLS-V2I1P102
Advances in Hematopoietic Stem Cell Transplantation: A Review of Recent Developments and Challenges
Moses Adondua Abah, Ovwigho-Ugbede, Oghenetejiri C, Micheal Abimbola Oladosu, Micah Nnabuko Okwah, Ochuele Dominic Agida, Ahinful Isaac Anku, Abah Sarah Onyeoche
| Received | Revised | Accepted | Published |
|---|---|---|---|
| 18 Jan 2026 | 17 Feb 2026 | 20 Mar 2026 | 30 Apr 2026 |
Citation
Moses Adondua Abah, Ovwigho-Ugbede, Oghenetejiri C, Micheal Abimbola Oladosu, Micah Nnabuko Okwah, Ochuele Dominic Agida, Ahinful Isaac Anku, Abah Sarah Onyeoche. “Advances in Hematopoietic Stem Cell Transplantation: A Review of Recent Developments and Challenges.” DS Reviews of Research in Life Sciences, vol. 2, no. 1, pp. 11-24, 2026.
Abstract
Keywords
Hematopoietic Stem Cell Transplantation, Graft-Versus-Host Disease, Conditioning regimens, Gene editing, Immunotherapy, Donor selection.
References
[1] M. Aljurf et al., “Worldwide Network for Blood and Marrow Transplantation (WBMT) Recommendations for Establishing a Hematopoietic Stem Cell Transplantation Program in Countries with Limited Resources (Part II): Clinical, Technical and Socio-Economic Considerations,” Hematology/Oncology and Stem Cell Therapy, vol. 13, no. 1, pp. 7-16, 2020.
[CrossRef] [Google Scholar] [Publisher Link]
[2] Maryam Alowaysi et al., “HLA-based Banking of Induced Pluripotent Stem Cells in Saudi Arabia,” Stem Cell Research and Therapy, vol. 14, no. 1, pp. 1-15, 2023.
[CrossRef] [Google Scholar] [Publisher Link]
[3] Panagiotis G. Asteris et al., “Survival Prediction in Allogeneic Haematopoietic Stem Cell Transplant Recipients using Pre- and Post-Transplant Factors and Computational Intelligence,” Journal of Cellular and Molecular Medicine, vol. 29, no. 16, pp. 1-9, 2025.
[CrossRef] [Google Scholar] [Publisher Link]
[4] C.V. Borlongan, “Bone Marrow Stem Cell Mobilization in Stroke: A Bonehead May be Good After All!,” Leukemia, vol. 25, no. 11, pp. 1674-1686, 2011.
[CrossRef] [Google Scholar] [Publisher Link]
[5] Andre Branco et al., “Advances in Ex Vivo Expansion of Hematopoietic Stem and Progenitor Cells for Clinical Applications,” Frontiers in Bioengineering and Biotechnology, vol. 12, pp. 1-29, 2024.
[CrossRef] [Google Scholar] [Publisher Link]
[6] Michael S Broder et al., “The Cost of Hematopoietic Stem-Cell Transplantation in the United States,” American Health and Drug Benefits, vol. 10, no. 7, pp. 366-374, 2017.
[Google Scholar] [Publisher Link]
[7] Michelle M. Chin et al., “Belumosudil Combination Therapy for Chronic Graft-Versus-Host-Disease in Real-World Clinical Practice,” Bone Marrow Transplantation, vol. 60, no. 3, pp. 393-395, 2025.
[CrossRef] [Google Scholar] [Publisher Link]
[8] Mahmood S. Choudhery, Taqdees Arif, and Ruhma Mahmood, “Applications of Artificial Intelligence in Stem Cell Therapy,” World Journal of Stem Cells, vol. 17, no. 8, pp. 1-15, 2025.
[CrossRef] [Google Scholar] [Publisher Link]
[9] Corey Cutler et al., “Belumosudil for Chronic Graft-Versus-Host Disease After 2 or More Prior Lines of Therapy: The Rockstar Study,” Blood, vol. 138, no. 22, pp. 2278-2289, 2021.
[CrossRef] [Google Scholar] [Publisher Link]
[10] Anne M. Dickinson et al., “Graft-Versus-Leukemia Effect Following Hematopoietic Stem Cell Transplantation for Leukemia,” Frontiers in Immunology, vol. 8, pp. 1-16, 2017.
[CrossRef] [Google Scholar] [Publisher Link]
[11] Anita D'Souza et al., “Current Use of and Trends in Hematopoietic Cell Transplantation in the United States,” Biology of Blood and Marrow Transplantation, vol. 26, no. 8, pp. e177-e182, 2020.
[CrossRef] [Google Scholar] [Publisher Link]
[12] Kelcee A. Everette et al., “Ex Vivo Prime Editing of Patient Haematopoietic Stem Cells Rescues Sickle-Cell Disease Phenotypes After Engraftment in Mice,” Nature Biomedical Engineering, vol. 7, no. 5, pp. 616-628, 2023.
[CrossRef] [Google Scholar] [Publisher Link]
[13] Haydar Frangoul et al., “Exagamglogene Autotemcel for Severe Sickle Cell Disease,” The New England Journal of Medicine, vol. 390, no. 18, pp. 1649-1662, 2024.
[CrossRef] [Google Scholar] [Publisher Link]
[14] Haydar Frangoul et al., “CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia,” The New England Journal of Medicine, vol. 384, no. 3, pp. 252-260, 2020.
[CrossRef] [Google Scholar] [Publisher Link]
[15] Arpita P. Gandhi, and Catherine J. Lee, “Telemedicine in Hematopoietic Cell Transplantation and Chimeric Antigen Receptor-T Cell Therapy,” Cancers, vol. 15, no. 16, pp. 1-16, 2023.
[CrossRef] [Google Scholar] [Publisher Link]
[16] Madjid Soltani Gerdfaramarzi et al., “Ethical Challenges of Cord Blood Banks: A Scoping Review,” Journal of Medicine and Life, vol. 15, no. 6, pp. 735-741, 2022.
[CrossRef] [Google Scholar] [Publisher Link]
[17] Ashley D. Hadjis, and Shannon R. McCurdy, “The Role and Novel use of Natural Killer Cells in Graft-Versus-Leukemia Reactions After Allogeneic Transplantation,” Frontiers in Immunology, vol. 15, pp. 1-18, 2024.
[CrossRef] [Google Scholar] [Publisher Link]
[18] Mitchell E. Horwitz et al., “Omidubicel vs Standard Myeloablative Umbilical Cord Blood Transplantation: Results of a Phase 3 Randomized Study,” Blood, vol. 138, no. 16, pp. 1429-1440, 2021.
[CrossRef] [Google Scholar] [Publisher Link]
[19] Lifen Huang et al., “Nanomedicine - A Promising Therapy for Hematological Malignancies,” Biomaterials Science, vol. 8, no. 9, pp. 2376-2393, 2020.
[CrossRef] [Google Scholar] [Publisher Link]
[20] Hidehiro Itonaga et al., “Allogeneic Transplantation of Bone Marrow Versus Peripheral Blood Stem Cells from HLA-Identical Relatives in Patients with Myelodysplastic Syndromes and Oligoblastic Acute Myeloid Leukemia: A Propensity Score Analysis of a Nationwide Database,” Annals of Hematology, vol. 102, no. 5, pp. 1215-1227, 2023.
[CrossRef] [Google Scholar] [Publisher Link]
[21] Hee-Je Kim et al., “Prognostic Value of Measurable Residual Disease Monitoring by Next-Generation Sequencing Before and After Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia,” Blood Cancer Journal, vol. 11, no. 6, pp. 1-11, 2021.
[CrossRef] [Google Scholar] [Publisher Link]
[22] John Koreth et al., “Interleukin-2 and Regulatory T Cells in Graft-Versus-Host Disease,” The New England Journal of Medicine, vol. 365, no. 22, pp. 2055-2066, 2011.
[CrossRef] [Google Scholar] [Publisher Link]
[23] Dwi Liliek Kusindarta, and Hevi Wihadmadyatami, “Conditioned Medium Derived from Bovine Umbilical Mesenchymal Stem Cells as an Alternative Source of Cell-Free Therapy,” Veterinary World, vol. 14, no. 10, pp. 2588-2595, 2021.
[CrossRef] [Google Scholar] [Publisher Link]
[24] Claire Lacan et al., “Bone Marrow Graft Versus Peripheral Blood Graft in Haploidentical Hematopoietic Stem Cells Transplantation: A Retrospective Analysis in1344 Patients of SFGM-TC Registry,” Journal of Hematology and Oncology, vol. 17, no. 1, pp. 1-5, 2024.
[CrossRef] [Google Scholar] [Publisher Link]
[25] Yee-Ching Lim, Soon-Keng Cheong, and Pooi-Pooi Leong, “Fibroblast-Derived Human iPSC Exhibits Superior Haematopoietic Potential Over Human ESC During Haematopoietic Differentiation,” Stem Cell Reviews and Repors, vol. 21, no. 4, pp. 1034-1047, 2025.
[CrossRef] [Google Scholar] [Publisher Link]
[26] Xinyi Liu et al., “Advances in CRISPR/Cas Gene Therapy for Inborn Errors of Immunity,” Frontiers in Immunology, vol. 14, pp. 1-24, 2023.
[CrossRef] [Google Scholar] [Publisher Link]
[27] Leo Luznik, Paul V. O'Donnell, and Ephraim J. Fuchs, “Post-Transplantation Cyclophosphamide for Tolerance Induction in HLA-Haploidentical Bone Marrow Transplantation,” Seminars in Oncology, vol. 39, no. 6, pp. 683-693, 2012.
[CrossRef] [Google Scholar] [Publisher Link]
[28] Neema P. Mayor et al., “The Impact of Patient Ethnicity on Haematopoietic Cell Transplantation Outcome: A Retrospective Cohort Study on the UK Experience,” The Lancet Haematology, vol. 11, no. 12, pp. e916-e926, 2024.
[CrossRef] [Google Scholar] [Publisher Link]
[29] Arnon Nagler et al., “Non-T-Depleted Haploidentical Transplantation with Post-Transplant Cyclophosphamide in Patients with Secondary Versus De Novo AML in First Complete Remission: An ALWP/EBMT Study,” Journal of Hematology and Oncology, vol. 16, no. 1, pp. 1-15, 2023.
[CrossRef] [Google Scholar] [Publisher Link]
[30] Gregory A. Newby et al., “Base Editing of Haematopoietic Stem Cells Rescues Sickle Cell Disease in Mice,” Nature, vol. 595, no. 7866, pp. 295-302, 2021.
[CrossRef] [Google Scholar] [Publisher Link]
[31] Elizabeth S. Ng et al., “Long-Term Engrafting Multilineage Hematopoietic Cells Differentiated from Human Induced Pluripotent Stem Cells,” Nature Biotechnology, vol. 43, no. 8, pp. 1274-1287, 2025.
[CrossRef] [Google Scholar] [Publisher Link]
[32] Dietger Niederwieser et al., “One and a Half Million Hematopoietic Stem Cell Transplants: Continuous and Differential Improvement in Worldwide Access with the use of Non-Identical Family Donors,” Haematologica, vol. 107, no. 5, pp. 1045-1053, 2021.
[CrossRef] [Google Scholar] [Publisher Link]
[33] Takuro Nishikawa, “Human Leukocyte Antigen-Haploidentical Haematopoietic Stem Cell Transplantation using Post-Transplant Cyclophosphamide for Paediatric Haematological Malignancies,” Cancers, vol. 16, no. 3, pp. 1-14, 2024.
[CrossRef] [Google Scholar] [Publisher Link]
[34] Richard J. O’Reilly, Susan Prockop, and Joseph H. Oved, “Virus-Specific T-Cells from Third Party or Transplant Donors for Treatment of EBV Lymphoproliferative Diseases Arising Post Hematopoietic Cell or Solid Organ Transplantation,” Frontiers in Immunology, vol. 14, pp. 1-17, 2023.
[CrossRef] [Google Scholar] [Publisher Link]
[35] Jakob R. Passweg et al., “Hematopoietic Cell Transplantation and Cellular Therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey,” Bone Marrow Transplantation, vol. 58, no. 6, pp. 647-658, 2023.
[CrossRef] [Google Scholar] [Publisher Link]
[36] Richard B. Presland, “Application of Proteomics to Graft-Versus-Host Disease: From Biomarker Discovery to Potential Clinical Applications,” Expert Review of Proteomics, vol. 14, no. 11, pp. 997-1006, 2017.
[CrossRef] [Google Scholar] [Publisher Link]
[37] Donna Przepiorka et al., “FDA Approval Summary: Belumosudil for Adult and Pediatric Patients 12 Years and Older with Chronic CvHD after Two or More Prior Lines of Systemic Therapy,” Clinical Cancer Research, vol. 28, no. 12, pp. 2488-2492, 2022.
[CrossRef] [Google Scholar] [Publisher Link]
[38] Tahereh Rostami et al., “Graft Failure After Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients with Acute Leukemia: Autologous Reconstitution or Second Transplant?,” Stem Cell Research and Therapy, vol. 15, no. 1, pp. 1-15, 2024.
[CrossRef] [Google Scholar] [Publisher Link]
[39] Alexander H. Schmidt, “Unrelated Hematopoietic Stem Cell Donor Registries: Present Reality and Future Prospects,” Current Opinion in Hematology, vol. 31, no. 6, pp. 251-260, 2024.
[CrossRef] [Google Scholar] [Publisher Link]
[40] Jamie Shoag et al., “Disparities in Access to Hematopoietic Cell Transplant Persist at a Transplant Center,” Bone Marrow Transplantation, vol. 59, no. 9, pp. 1258-1264, 2024.
[CrossRef] [Google Scholar] [Publisher Link]
[41] Anusha Sudulaguntla et al., “A Review: Stem Cells and Classification of Stem Cells based on their Origin,” World Journal of Pharmacy and Pharmaceutical Sciences, vol. 5, no. 11, pp. 534-556, 2016.
[CrossRef] [Google Scholar] [Publisher Link]
[42] Inigo Terrén et al., “Cytokine-Induced Memory-Like NK Cells: From the basics to Clinical Applications,” Frontiers in Immunology, vol. 13, pp. 1-8, 2022.
[CrossRef] [Google Scholar] [Publisher Link]
[43] U.S. Food and Drug Administration, FDA Approves Belumosudil for Chronic Graft-Versus-Host Disease, 2021. [Online]. Available: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-belumosudil-chronic-graft-versus-host-disease
[44] U.S. Food and Drug Administration, FDA Approves Omidubicel to Reduce Time to Neutrophil Recovery and Infection in Patients with Hematologic Malignancies, 2023. [Online]. Available: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-omidubicel-reduce-time-neutrophil-recovery-and-infection-patients-hematologic
[45] U.S. Food and Drug Administration, Human Gene Therapy Products Incorporating Human Genome Editing: Guidance for Industry, 2024. [Online]. Available: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/human-gene-therapy-products-incorporating-human-genome-editing
[46] Caterina Giovanna Valentini, Claudio Pellegrino, and Luciana Teofili, “Pros and Cons of Cryopreserving Allogeneic Stem Cell Products,” Cells, vol. 13, no. 6, pp. 1-24, 2024.
[CrossRef] [Google Scholar] [Publisher Link]
[47] World Health Organization, Human Genome Editing: A Framework for Governance, World Health Organization, 2021. [Online]. Available: https://www.who.int/publications/i/item/9789240030060
[48] Zheng-Li Xu et al., “Clinical Outcomes of Three Haploidentical Transplantation Protocols for Hematologic Malignancies based on Data from the Chinese Bone Marrow Transplantation Registry Group,” Haematologica, vol. 110, no. 3, pp. 629-639, 2024.
[CrossRef] [Google Scholar] [Publisher Link]
[49] Robert Zeiser et al., “Novel Therapies for Graft Versus Host Disease with a Focus on Cell Therapies,” Frontiers in Immunology, vol. 14, 2023.
[50] Robert Zeiser et al., “Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-Versus-Host Disease,” The New England Journal of Medicine, vol. 385, no. 3, pp. 228-238, 2021.
[CrossRef] [Google Scholar] [Publisher Link]
[51] Zhao Zhang et al., “Peripheral Blood Stem Cell Transplantation vs. Bone Marrow Transplantation for Aplastic Anemia: A Systematic Review and Meta-Analysis,” Frontiers in Medicine, vol. 10, pp. 1-9, 2023.
[CrossRef] [Google Scholar] [Publisher Link]
[52] Yan-Li Zhao et al., “Integrating CAR T-Cell Therapy and Transplantation: Comparisons of Safety and Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation After CAR T-Cell or Chemotherapy-based Complete Remission in B-Cell Acute Lymphoblastic Leukemia,” Frontiers in Immunology, vol. 12, 2021.
[CrossRef] [Google Scholar] [Publisher Link]
[53] Delian Zhou, Xiaojian Zhu, and Yi Xiao, “CAR-T Cell Combination Therapies in Hematologic Malignancies,” Experimental Hematology and Oncology, vol. 13, no. 1, pp. 1-12, 2024.
[CrossRef] [Google Scholar] [Publisher Link]